JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies
The use of a highly-effective treatment for multiple sclerosis (MS) is associated with a severe risk of developing complications, such as progressive multifocal leukoencephalopathy (PML) caused by the John Cunningham virus (JCV). The aim of this study was to evaluate the correlation between anti-JCV...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/9/1998 |
id |
doaj-2c1d72d010db438aae314e15f9a22f79 |
---|---|
record_format |
Article |
spelling |
doaj-2c1d72d010db438aae314e15f9a22f792021-05-31T23:21:15ZengMDPI AGJournal of Clinical Medicine2077-03832021-05-01101998199810.3390/jcm10091998JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive TherapiesRobert Bonek0Wojciech Guenter1Robert Jałowiński2Anna Karbicka3Anna Litwin4Maciej Maciejowski5Radosław Zajdel6Karolina Zajdel7Veronique Petit8Konrad Rejdak9Department of Neurology and Clinical Neuroimmunology, Regional Specialist Hospital, 86-300 Grudziadz, PolandDepartment of Clinical Neuropsychology, Nicolaus Copernicus University, 87-100 Torun, Poland, and Collegium Medicum, 85-094 Bydgoszcz, PolandDepartment of Neurology, Regional Hospital, 71-455 Szczecin, PolandDepartment of Neurology, Regional Hospital, 71-455 Szczecin, PolandDepartment of Neurology, Regional Hospital, 10-561 Olsztyn, PolandKMK Clinical, MS Center, 40-571 Katowice, PolandChair of Business Informatics, University of Lodz, 90-214 Lodz, PolandDepartment of Medical Informatics and Statistics, Medical University of Lodz, 90-645 Lodz, PolandDepartment of Neurology, Medical University of Lublin, 20-090 Lublin, PolandDepartment of Neurology, Medical University of Lublin, 20-090 Lublin, PolandThe use of a highly-effective treatment for multiple sclerosis (MS) is associated with a severe risk of developing complications, such as progressive multifocal leukoencephalopathy (PML) caused by the John Cunningham virus (JCV). The aim of this study was to evaluate the correlation between anti-JCV Ab seroprevalence, anti-JCV AI, demographic and clinical factors as well as the type of therapy used in the Polish MS population. This is a multicentre, prospective and cross-sectional study involving 1405 MS patients. The seroprevalence of anti-JCV Ab and anti-JCV AI levels as well as AI categories were analysed with the use of a second-generation two-step ELISA test (STRATIFY JCV DxSelect). The overall prevalence of anti-JCV Ab was 65.8%. It was shown that seroprevalence increases with the patient’s age. The seroprevalence was significantly associated with the treatment type, and the highest values (76%) were obtained from immunosuppressant-treated patients. Overall, 63.3% of seropositive patients had an antibody index (AI) level of >1.5. In the seropositive patient group, the mean AI level amounted to 2.09. Similarly to the seroprevalence, AI levels correlated with the patient’s age; AI level for patients above 40 years old and from subsequent age quintiles plateaued, amounting to at least 1.55. Patients treated with immunosuppressants and immunomodulatory drugs obtained the highest (1.67) and lowest (1.35) AI levels, respectively. Of the immunosuppressants used, the highest mean AI levels were observed in mitoxantrone and cladribine groups, amounting to 1.75 and 1.69, respectively. In patients treated with immunomodulatory drugs, the lowest AI levels were observed in the dimethyl fumarate (DMF) group (1.11). The seroprevalence rate in the Polish MS population is one of the highest in Europe. The majority of seropositive patients had an anti-JCV Ab level qualifying them for a high-risk category. The highest mean AI levels are observed in patients receiving immunosuppressants, especially mitoxantrone and cladribine. Patients receiving immunomodulatory drugs have lower AI levels compared to treatment-naïve subjects, especially when treated with DMF. Further studies, especially longitudinal studies, are required to determine the impact of MS drugs on the seroprevalence of anti-JCV Ab and AI levels.https://www.mdpi.com/2077-0383/10/9/1998multiple sclerosisJohn Cunningham virusanti-JCV antibodyantibody indexdisease-modifying therapies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Robert Bonek Wojciech Guenter Robert Jałowiński Anna Karbicka Anna Litwin Maciej Maciejowski Radosław Zajdel Karolina Zajdel Veronique Petit Konrad Rejdak |
spellingShingle |
Robert Bonek Wojciech Guenter Robert Jałowiński Anna Karbicka Anna Litwin Maciej Maciejowski Radosław Zajdel Karolina Zajdel Veronique Petit Konrad Rejdak JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies Journal of Clinical Medicine multiple sclerosis John Cunningham virus anti-JCV antibody antibody index disease-modifying therapies |
author_facet |
Robert Bonek Wojciech Guenter Robert Jałowiński Anna Karbicka Anna Litwin Maciej Maciejowski Radosław Zajdel Karolina Zajdel Veronique Petit Konrad Rejdak |
author_sort |
Robert Bonek |
title |
JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies |
title_short |
JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies |
title_full |
JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies |
title_fullStr |
JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies |
title_full_unstemmed |
JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies |
title_sort |
jc virus seroprevalence and jcvab index in polish multiple sclerosis patients treated with immunomodulating or immunosuppressive therapies |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2021-05-01 |
description |
The use of a highly-effective treatment for multiple sclerosis (MS) is associated with a severe risk of developing complications, such as progressive multifocal leukoencephalopathy (PML) caused by the John Cunningham virus (JCV). The aim of this study was to evaluate the correlation between anti-JCV Ab seroprevalence, anti-JCV AI, demographic and clinical factors as well as the type of therapy used in the Polish MS population. This is a multicentre, prospective and cross-sectional study involving 1405 MS patients. The seroprevalence of anti-JCV Ab and anti-JCV AI levels as well as AI categories were analysed with the use of a second-generation two-step ELISA test (STRATIFY JCV DxSelect). The overall prevalence of anti-JCV Ab was 65.8%. It was shown that seroprevalence increases with the patient’s age. The seroprevalence was significantly associated with the treatment type, and the highest values (76%) were obtained from immunosuppressant-treated patients. Overall, 63.3% of seropositive patients had an antibody index (AI) level of >1.5. In the seropositive patient group, the mean AI level amounted to 2.09. Similarly to the seroprevalence, AI levels correlated with the patient’s age; AI level for patients above 40 years old and from subsequent age quintiles plateaued, amounting to at least 1.55. Patients treated with immunosuppressants and immunomodulatory drugs obtained the highest (1.67) and lowest (1.35) AI levels, respectively. Of the immunosuppressants used, the highest mean AI levels were observed in mitoxantrone and cladribine groups, amounting to 1.75 and 1.69, respectively. In patients treated with immunomodulatory drugs, the lowest AI levels were observed in the dimethyl fumarate (DMF) group (1.11). The seroprevalence rate in the Polish MS population is one of the highest in Europe. The majority of seropositive patients had an anti-JCV Ab level qualifying them for a high-risk category. The highest mean AI levels are observed in patients receiving immunosuppressants, especially mitoxantrone and cladribine. Patients receiving immunomodulatory drugs have lower AI levels compared to treatment-naïve subjects, especially when treated with DMF. Further studies, especially longitudinal studies, are required to determine the impact of MS drugs on the seroprevalence of anti-JCV Ab and AI levels. |
topic |
multiple sclerosis John Cunningham virus anti-JCV antibody antibody index disease-modifying therapies |
url |
https://www.mdpi.com/2077-0383/10/9/1998 |
work_keys_str_mv |
AT robertbonek jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosispatientstreatedwithimmunomodulatingorimmunosuppressivetherapies AT wojciechguenter jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosispatientstreatedwithimmunomodulatingorimmunosuppressivetherapies AT robertjałowinski jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosispatientstreatedwithimmunomodulatingorimmunosuppressivetherapies AT annakarbicka jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosispatientstreatedwithimmunomodulatingorimmunosuppressivetherapies AT annalitwin jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosispatientstreatedwithimmunomodulatingorimmunosuppressivetherapies AT maciejmaciejowski jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosispatientstreatedwithimmunomodulatingorimmunosuppressivetherapies AT radosławzajdel jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosispatientstreatedwithimmunomodulatingorimmunosuppressivetherapies AT karolinazajdel jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosispatientstreatedwithimmunomodulatingorimmunosuppressivetherapies AT veroniquepetit jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosispatientstreatedwithimmunomodulatingorimmunosuppressivetherapies AT konradrejdak jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosispatientstreatedwithimmunomodulatingorimmunosuppressivetherapies |
_version_ |
1721417696544817152 |